Side Effects, Interactions, Warning, Dosage & Uses. CLINICAL PHARMACOLOGYMechanism Of Action. Orlistat is a reversible inhibitor of gastrointestinal. It exerts its therapeutic activity in the lumen of the stomach and. The inactivated enzymes are thus unavailable. As undigested triglycerides are not absorbed.
Pharmacodynamics. Dose- response Relationship. The dose- response relationship for orlistat in human. Figure 1. The effect is the percentage of ingested fat. Both individual data (open.
Figure 1. Figure 1 : Dose- Response Relationship for Orlistat in. Human Volunteers. At the recommended therapeutic dose of 1. Ethanol does not affect orlistat's effect on preventing. Other Short- term Studies.
Adults. In several studies of up to 6- weeks duration, the effects. XENICAL on gastrointestinal and systemic physiological. Postprandialcholecystokinin plasma concentrations were lowered after multiple doses of XENICAL. There were no clinically significant changes observed in.
In addition, no effects on plasma triglyceride levels. XENICAL in these. In a 3- week study of 2. XENICAL (1. 20 mg three. Pediatrics. In a 3- week study of 3. XENICAL (1. 20 mg three times a day) did not significantly affect the. The iron balance.
Following oral. dosing with 3. C- orlistat, plasma radioactivity peaked at. L). In therapeutic studies involving monitoring of. L or 0. 0. 2 . Orlistat minimally. Metabolism. Based on an oral 1. C- orlistat mass balance.
Spirulina is a non-toxic blue-green algae. It is a source of phycocyanobilin. Preliminary evidence suggests spirulina is remarkably potent at protecting the brain and. Common Side Effects of Albuterol. You should tell your doctor if any of the following side effects of albuterol become severe or don't go away: Nervousness. Dietary supplements that contain ephedra alkaloids (sometimes called ma huang) are widely promoted and used in the United States as a means of losing weight and.
M1 ((the hydrolyzed . M1 and M3 have an open .
In view of this low inhibitory activity and the low plasma. L and 1. 08 ng/m.
Both ephedrine and pseudoephedrine increase blood pressure and act as bronchodilators, with pseudoephedrine having considerably less effect. Weight loss. How to use selegiline: Use selegiline as directed by your doctor. Check the label on the medicine for exact dosing instructions. Take selegiline by mouth with food. What are the possible side effects of orlistat (alli, Xenical)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty. Nasal congestion, also known as stuffy nose or stuffed up nose, nasal blockage, blocked nose, or nasal obstruction is a condition that exists when the nasal passages. Supplements with Similar Side Effects as: 5-Hydroxytryptophan (5-HTP) Supplements with Similar Side Effects as: Alpha-Linolenic Acid (ALA) Supplements with Similar. Welcome to PDR+ for Patients. Search or browse the over 2,300 drug guides by drug name to view trusted, reliable drug guides written for the patient and available on. MedWatch alerts provide timely new safety information on human drugs, medical devices, vaccines and other biologics, dietary supplements, and cosmetics.
L for M1 and. M3, respectively, 2 to 4 hours after a dose), these metabolites are considered. The primary metabolite M1 had a short. M3. eliminated at a slower rate (half- life approximately 1. Elimination. Following a single oral dose of 3. C- orlistat. in both normal weight and obese subjects, fecal excretion of the unabsorbed. Orlistat and its M1 and M3.
Approximately 9. 7% of the. The cumulative renal excretion of total radioactivity was. C- orlistat. The time to reach. The disposition of. Based. on limited data, the half- life of the absorbed orlistat is in the range of 1 to. Specific Populations.
No pharmacokinetic study was conducted for specific. Drug Interactions. Alcohol. In a multiple- dose study in 3. XENICAL and 4. 0 grams of alcohol (e.
Amiodarone. In a pharmacokinetic study conducted in healthy. Day 1. 4 co- administered with a single. Day 4, a 2. 3 – 2. The effect of commencing orlistat treatment in patients on. Cyclosporine. In a multiple- dose study, coadministration of 5. XENICAL three times daily decreased. AUC and Cmax by 3.
In the same study. XENICAL three times daily decreased cyclosporine AUC. Cmax by 1. 7% and 4%, respectively. Digoxin. In 1. 2 normal- weight subjects receiving XENICAL 1. XENICAL did not alter the pharmacokinetics of a. Fat- soluble Vitamin Supplements and Analogues.
A pharmacokinetic interaction study showed a 3. XENICAL. XENICAL inhibited absorption of a vitamin E acetate supplement. The effect of XENICAL on the absorption of supplemental. D, vitamin A, and nutritionally- derived vitamin K is not known at this. Glyburide. In 1. 2 normal- weight subjects receiving orlistat 8.
Nifedipine (extended- release tablets)In 1. XENICAL 1. 20 mg. XENICAL did not alter the bioavailability of. Oral Contraceptives. In 2. 0 normal- weight female subjects, the treatment of. XENICAL 1. 20 mg three times a day for 2. Phenytoin. In 1. 2 normal- weight subjects receiving XENICAL 1.
XENICAL did not alter the pharmacokinetics of a. Pravastatin. In a 2- way crossover study of 2. XENICAL 1. 20 mg three times a day for 6. XENICAL did not affect the pharmacokinetics of pravastatin. Warfarin. In 1. 2 normal- weight subjects, administration of XENICAL.
R- and S- enantiomers) or pharmacodynamics. Factor VII). Although undercarboxylated osteocalcin. K nutritional status, was unaltered with XENICAL. K levels tended to decline in subjects taking XENICAL. During the first year of therapy, the.
During. the second year of therapy, some studies assessed continued weight loss and. XENICAL on weight regain. The majority of these. In the XENDOS study. Caucasians. 1% other), the time to onset of type 2 diabetes was assessed in addition to. In all these studies, treatment with XENICAL and placebo. XENICAL plus diet and placebo plus diet.
During the weight loss and weight maintenance period, a. In addition, all patients were offered. One- year Results : Weight Loss, Weight Maintenance, And Risk.
Factors. Pooled data from five clinical trials indicated that the. XENICAL. and 5. 8 lbs in the placebo- treated patients. After 1 year of treatment, the. XENICAL- treated patients and. One thousand seventy two (6. XENICAL and 7. 01 (6. Of the patients who completed 1 year of treatment, 5.
XENICAL (1. 20 mg three times a day) and 3. The percentages of patients achieving . Study 1. 4 1. 61 was. The relative changes in risk factors associated with. XENICAL and placebo are presented for. Population as a Whole. The changes in metabolic, cardiovascular and.
Table 7. One year of therapy with XENICAL. Table 7 : Mean Change in Risk Factors From Randomization.
Following 1- Year Treatment Population as a Whole. Risk Factor. XENICAL 1. HDL increased in the placebo group by 2. XENICAL group by. In the population with abnormal blood pressure at baseline (systolic. BP. . For patients with a diastolic. Fasting insulin decreased more.
XENICAL than placebo (- 3. L) from randomization to 1 year in.
A greater. reduction in waist circumference for XENICAL vs placebo (- 7. The diet utilized during the.
For studies 1. 41. C and 1. 41. 85, patients'. XENICAL in conjunction. Study 1. 43. 02 was conducted to evaluate the. XENICAL on weight regain in patients who.
In study 1. 41. 19. C, patients treated with placebo regained. XENICAL regained 2.
In. study 1. 41. 85, patients treated with placebo regained 6. XENICAL regained 3. In study 1. 43. 02, patients treated with placebo regained 5. XENICAL. regained 3. Two- year Results : Long- term Weight Control And Risk. Factors. The treatment effects of XENICAL were examined for 2. Table 6). At the end of year 1, the patients' diets were.
The diet prescribed in the second year. XENICAL was shown to be more. Pooled data from four clinical studies indicate that 7. XENICAL and 7. 6% of.
Pooled. data from four clinical studies indicate that the mean weight loss difference. XENICAL 1. 20 mg three times a day and placebo treatment groups at year 2. ITT LOCF) was 3%. In the. same studies cited in the One- year Results (see Table 6), the percentages. Study 1. 4 1. 61 was.
The relative changes in risk factors associated with. Population as a Whole. The relative differences in risk factors between. XENICAL and placebo were similar to the results following 1 year.
LDL- cholesterol, LDL/HDL ratio, triglycerides. The relative differences between. HDL cholesterol and systolic blood pressure were less than. Population With Abnormal Risk Factors at Randomization.
The relative differences in risk factors between. XENICAL and placebo were similar to the results following 1 year. LDL- and HDL- cholesterol, triglycerides, fasting insulin, diastolic. The relative differences between.
LDL/HDL ratio and isolated systolic blood pressure were. Four- year Results : Long- term Weight Control And Risk. Factors. In the 4- year double- blind, placebo- controlled XENDOS. XENICAL in delaying the onset of type 2 diabetes and on. Thirty- four percent of the. XENICAL group completed the 4- year study. At the end of the study, the mean percent weight loss in.
XENICAL group. (p < 0. Figure 2). Forty- five percent of the placebo patients and 7. XENICAL patients lost .
Following 4. years of treatment, 2. XENICAL patients. This finding was. Table 1. 0 and Figure 3). XENICAL did not reduce the risk for the.
The effect of XENICAL to delay the onset of type 2. IGT is presumably due to weight loss, and not. The effect. of XENICAL on weight loss is adjunctive to diet and exercise. Table 1. 0 : Incidence Rate of Diabetes at Year 4 by.
OGTT Status at Baseline*OGTT at Baseline. Normal. Impaired. All. Treatment. Placebo. XENICALPlacebo. XENICALPlacebo.
XENICALNumber of patients*1. Life table rate. Thirty percent of. XENICAL achieved at least a 5% or greater reduction in.
For HDL cholesterol, there was a +6. XENICAL and +8. 6% increase on placebo, p > 0. Systolic blood pressure. Hg on XENICAL and increased by +4. Hg on placebo. p > 0. Diastolic blood pressure decreased by - 0. Hg for XENICAL and by.
Hg for placebo, p > 0. Glucose Tolerance In Obese Patients. Two- year studies that included oral glucose tolerance.
OGTT) status at. randomization was either normal, impaired, or diabetic. The progression from a normal OGTT at randomization to a. OGTT following 2 years of treatment with XENICAL (n=2. Following treatment with XENICAL, 0. In patients found to have an impaired OGTT at. XENICAL compared to.
After 1 year of treatment, 4. XENICAL patients had a normal oral glucose tolerance test while. XENICAL patients became diabetic.
All study. participants had a baseline BMI that was 2 units greater than the US weighted. Body mass index was the primary. During the study, all patients were instructed to take a.
XENICAL. Patients were also maintained on a well- balanced, reduced- calorie. In addition, all. Approximately 6. 5% of patients in each treatment group. Following one year of treatment, BMI decreased by an.
Ephedrine - Wikipedia. Ephedrine(1. R,2. S)- (. It has also been used for asthma, narcolepsy, and obesity but is not the preferred treatment. It is of unclear benefit in nasal congestion. It can be taken by mouth or by injection into a muscle, vein, or just under the skin. Onset with intravenous use is fast, while injection into a muscle can take 2.
When given by injection it lasts about an hour and when taken by mouth it can last up to four hours. Serious side effects include stroke, heart attack, and abuse. Dietary supplements that contain ephedrine are illegal in the United States. An exception is when used in traditional Chinese medicine. Both ephedrine and pseudoephedrine increase blood pressure and act as bronchodilators, with pseudoephedrine having considerably less effect.
Ephedrine also decreases gastric emptying. Methylxanthines such as caffeine and theophylline have a synergistic effect with ephedrine with respect to weight loss. This led to creation and marketing of compound products.
It is a popular supplement taken by bodybuilders seeking to cut body fat before a competition. Because of ephedrine's structural similarity to methamphetamine, it can be used to create methamphetamine using chemical reduction in which ephedrine's hydroxyl group is removed; this has made ephedrine a highly sought- after chemical precursor in the illicit manufacture of methamphetamine. The most popular method for reducing ephedrine to methamphetamine is similar to the Birch reduction, in that it uses anhydrous ammonia and lithium metal in the reaction. The second- most popular method uses red phosphorus, iodine, and ephedrine in the reaction.
Through oxidation, ephedrine can be easily synthesized into methcathinone. Ephedrine is listed as a table- I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Many commercial immunoassay screening tests directed at the amphetamines cross- react appreciably with ephedrine, but chromatographic techniques can easily distinguish ephedrine from other phenethylamine derivatives. Blood or plasma ephedrine concentrations are typically in the 2.
The current WADA limit for ephedrine in an athlete's urine is 1. Its action bears more resemblance to amphetamine than to fluoxetine in that its primary mode of therapeutic action involves norepinephrine and to a lesser degree dopamine, but it also releases some serotonin from presynaptic clefts. It should not be used with ephedrine, as it may increase the likelihood of side effects. Ephedrine should be used with caution in patients with inadequate fluid replacement, impaired adrenal function, hypoxia, hypercapnia, acidosis, hypertension, hyperthyroidism, prostatic hypertrophy, diabetes mellitus, cardiovascular disease, during delivery if maternal blood pressure is > 1. Hg, and lactation.
ADRs associated with ephedrine therapy include. It is similar in molecular structure to phenylpropanolamine, methamphetamine, and epinephrine (adrenaline). Chemically, it is an alkaloid with a phenethylamine skeleton found in various plants in the genus Ephedra (family Ephedraceae). It works mainly by increasing the activity of norepinephrine (noradrenaline) on adrenergic receptors.
By convention, the pair of enantiomers with the stereochemistry (1. R,2. S) and (1. S,2. R) is designated ephedrine, while the pair of enantiomers with the stereochemistry (1. R,2. R) and (1. S,2. S) is called pseudoephedrine.
Ephedrine is a substituted amphetamine and a structural methamphetamine analogue. It differs from methamphetamine only by the presence of a hydroxyl group (—OH). The isomer which is marketed is (1. R,2. S)- (–)- ephedrine.
The result is that the levorotary l- ephedrine is wrongly named L- ephedrine and the dextrorotary d- pseudoephedrine (the diastereomer) wrongly D- pseudoephedrine. The IUPAC names of the two enantiomers are (1. R,2. S)- respectively (1. S,2. R)- 2- methylamino- 1- phenylpropan- 1- ol. A synonym is erythro- ephedrine.
Raw materials for the manufacture of ephedrine and traditional Chinese medicines are produced in China on a large scale. As of 2. 00. 7, companies produced for export US$1. Chinese medicine. Methylation of this product would then produce ephedrine. This pathway has since been disproven. The product is then reacted with a retro- aldolase, forming benzaldehyde.
Benzaldehyde reacts with pyruvic acid to attach a 2 carbon unit. This product then undergoes transamination and methylation to form ephedrine and its stereoisomer, pseudoephedrine. The principal mechanism of action relies on its indirect stimulation of the adrenergic receptor system by increasing the activity of norepinephrine at the postsynaptic . Ephedrine, though, binds better than N- methylephedrine, which has an additional methyl group at the nitrogen atom. Also the steric orientation of the hydroxyl group is important for receptor binding and functional activity.
The industrial manufacture of ephedrine in China began in the 1. Merck began marketing and selling the drug as ephetonin. Ephedrine exports between China and the West grew from 4 to 2.
District Court for the District of Utah ruled the FDA did not have proper evidence that low dosages of ephedrine alkaloids are actually unsafe. Court of Appeals for the Tenth Circuit in Denver upheld the FDA's final rule declaring all dietary supplements containing ephedrine alkaloids adulterated, and therefore illegal for marketing in the United States. Purchasing is currently limited and monitored, with specifics varying from state to state.
The House passed the Combat Methamphetamine Epidemic Act of 2. USA PATRIOT Act. Signed into law by President George W. Bush on March 6, 2. US Code (2. 1 USC 8. The federal statute included these requirements for merchants who sell these products: A retrievable record of all purchases identifying the name and address of each party to be kept for two years.
Required verification of proof of identity of all purchasers. Required protection and disclosure methods in the collection of personal information. Reports to the Attorney General of any suspicious payments or disappearances of the regulated products.
Non- liquid dose form of regulated product may only be sold in unit- dose blister packs. Regulated products are to be sold behind the counter or in a locked cabinet in such a way as to restrict access. Daily sales of regulated products not to exceed 3. Monthly sales not to exceed 9 g of pseudoephedrine base in regulated products. The law gives similar regulations to mail- order purchases, except the monthly sales limit is only 7.
As a pure herb or tea, m. The law restricts/prohibits its being sold as a dietary supplement (pill) or as an ingredient/additive to other products, like diet pills.
Australia. Lower than 8 mg pills are still available Otc for sinus, head colds and flu, but is completely illegal in over the counter weight loss products. Germany. Afterwards, access was restricted since it was mostly bought for unindicated uses. Similarly, ephedra can only be bought with a prescription. Since April 2. 00.
The American Society of Health- System Pharmacists. Retrieved Jan 2. 01. Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN 9. 78. 16. 08. Retrieved 2. 7 January 2. Preuss, eds. Obesity epidemiology, pathophysiology, and prevention (2nd ed.).
Boca Raton, Florida: CRC Press. ISBN 9. 78. 14. 39. World Health Organization. Retrieved 8 December 2. International drug price indicator guide.
Retrieved January 2. Tarascon pocket pharmacopoeia 2. Jones & Bartlett Learning. ISBN 9. 78. 12. 84. Br J Clin Pharmacol. PMC 1. 42. 94. 47 . PMID 6. 87. 50. 0.
G.; Hardy, M. L.; Morton, S. C.; Maglione, M.; Mojica, W. A.; Suttorp, M. J.; Rhodes, S.
L.; Jungvig, L.; Gagn. JAMA: The Journal of the American Medical Association. PMID 1. 26. 72. 77.
T.; Allison, D. B.; Coates, P. Journal of the American Dietetic Association.
S8. 0–S8. 6. PMID 1. Bray; Claude Bouchard (2.
Handbook of obesity. ISBN 9. 78- 0- 8. Sports medicine (Auckland, N. Z.). 3. 4 (1. 3): 8. PMID 1. 54. 87. 90.
The World Anti- Doping Code, World Anti- Doping Agency, Montreal, Canada, 2. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2. Mayne Pharma. Ephedrine sulfate injection DBL (Approved Product Information). Melbourne: Mayne Pharma; 2.
Palamar J (January 2. Health Policy (Review). PMID 2. 06. 85. 00. British National Formulary, 4. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2. ISBN0- 8. 53. 69- 5.
Txsci. oxfordjournals (2. Borsato, Giuseppe; Linden, Anthony; De Lucchi, Ottorino; Lucchini, Vittorio; Wolstenholme, David; Zambon, Alfonso (2.
Chem. 7. 2 (1. 1): 4. PHYTOTHERAPY RESEARCH. Edited by Reynolds JEF, ed. Martindale: The complete drug reference (2. London: Pharmaceutical Press. ISBN 0- 8. 53. 69- 2. The Merck Index: An encyclopedia of chemicals, drugs, and biologicals, 1.
Whitehouse Station: Merck^Patil, Popat N.; Tye, A.; La. Pidus, J. B. 1. 48 (2): 1. Chem Bio Chem. PMID 1. Journal of the American Chemical Society. ISSN 0. 00. 2- 7. Retrieved May 9, 2.
November 5, 2. 00. Phytochemistry. 1. Retrieved 2. 01. 5- 0. Pharmacological Effects of Ephedrine Alkaloids on Human . PDF^Shigeaki Kobayashi, et al. The Sympathomimetic Actions of l- Ephedrine and d- Pseudoephedrine: Direct Receptor Activation or Norepinephrine Release?
Anesth Analg 2. 00. Munhall, AC; Johnson, SW (2. PMID 1. 63. 86. 71. Levy; Kavita Kalidas (2.
February 2. 01. 0). Principles of Addictions and the Law: Applications in Forensic, Mental Health, and Medical Practice. Academic Press. ISBN 9. Narcotic Culture: A History of Drugs in China. University of Chicago Press. ISBN 9. 78- 0- 2. Clinical Toxicology.
Philadelphia: WB Saunders; 2. ISBN0- 7. 21. 6- 5. Research Laboratories; 1. ISBN0- 9. 11. 91. Health Canada. January 9, 2. Archived from the original on February 6, 2.
Retrieved July 7, 2. European Annals of Otorhinolaryngology, Head and Neck Diseases.